Alpha DNA Investment Management’s Oaktree Specialty Lending OCSL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-57,375
Closed -$1.08M – 204
2023
Q1
$1.08M Buy
+57,375
New +$1.14M 0.32% 86
2022
Q3
– Sell
-53,739
Closed -$1.05M – 186
2022
Q2
$1.05M Buy
+53,739
New +$1.13M 0.9% 37

Other funds holding OCSL

Alpha DNA Investment Management's OCSL Position: Q2 2023 in Review

Alpha DNA Investment Management sold out of Oaktree Specialty Lending (OCSL) in Q2 2023, closing a stake of 57,375 shares — an estimated $1.08M sold.

Alpha DNA Investment Management first reported a position in OCSL in Q2 2022 and held it in 2 quarters. The position peaked at $1.08M in Q1 2023. 183 funds tracked by Wall St. Rank hold OCSL as of Q2 2023.

  • Alpha DNA Investment Management reported no remaining Oaktree Specialty Lending position as of Q2 2023 after selling out during the quarter.
  • Alpha DNA Investment Management sold 57,375 Oaktree Specialty Lending shares in Q2 2023, an estimated $1.08M.
  • Alpha DNA Investment Management first reported a position in Oaktree Specialty Lending in Q2 2022 and held it in 2 quarters.
  • Alpha DNA Investment Management's Oaktree Specialty Lending position peaked at $1.08M in Q1 2023.
  • 183 funds tracked by Wall St. Rank held Oaktree Specialty Lending as of Q2 2023.

Based on Alpha DNA Investment Management's 13F filing for Q2 2023, filed 31 Jul 2023.